New data shows nipocalimab significantly improves dry mouth symptoms in Sjögren’s syndrome patients
New data from Johnson & Johnson’s Phase 2 clinical study reveals that nipocalimab demonstrates promising results in improving dry mouth symptoms associated with Sjögren’s syndrome.